Onconetix (NASDAQ:ONCO – Get Free Report) and Celularity (NASDAQ:CELU – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.
Valuation & Earnings
This table compares Onconetix and Celularity”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Onconetix | $810,000.00 | 2.12 | -$14.03 million | $2,481.20 | 0.00 |
| Celularity | $18.67 million | 1.09 | -$91.72 million | ($1.69) | -0.37 |
Onconetix has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Onconetix and Celularity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Onconetix | -1,575.89% | -91.95% | -53.76% |
| Celularity | -246.65% | N/A | -48.20% |
Insider & Institutional Ownership
23.9% of Onconetix shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Onconetix has a beta of 2.62, suggesting that its stock price is 162% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Onconetix and Celularity, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
| Celularity | 1 | 0 | 0 | 0 | 1.00 |
Summary
Onconetix beats Celularity on 6 of the 11 factors compared between the two stocks.
About Onconetix
Onconetix, Inc. is a biotechnology company focused on developing and commercializing diagnostic and therapeutic products for men’s health. The company’s portfolio is centered primarily on prostate health, with products intended to support the detection, risk assessment and treatment of prostate-related conditions. Its lead diagnostic product is Proclarix, a blood-based test designed to help assess the risk of clinically significant prostate cancer in men with elevated prostate-specific antigen (PSA) levels.
About Celularity
Celularity is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease. The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
